Sonendo, Inc.: management transactions · United States · SEC (Form 4)

About Sonendo, Inc.

Sonendo, Inc. is a U.S.-based medical technology company operating in the United States and listed on the OTC market under the ticker SONX, rather than on the NYSE or NASDAQ at present. Headquartered in Laguna Hills, California, the company focuses on a highly specialized segment of dental healthcare: endodontics. Its flagship platform is the GentleWave® System, an advanced root-canal cleaning and disinfection technology designed to help preserve tooth structure while reducing the invasiveness of conventional treatment. Sonendo’s business model is centered on the development, manufacturing, and commercialization of a proprietary procedural platform used by dental professionals. The GentleWave System combines fluid dynamics and acoustic energy to clean and disinfect the microscopic spaces inside teeth. Management positions the technology as a clinically meaningful alternative to traditional root-canal approaches because it aims to remove less tooth structure and deliver more effective cleaning in complex anatomy. In practical terms, the company’s offering is not just a one-off device sale: it also includes procedure-related consumables and accessories, which can support recurring revenue over time if adoption expands. Founded to improve the standard of care in root-canal therapy, Sonendo built its identity around a single, focused therapeutic category. That narrow specialization is a strategic strength and a risk. On the positive side, it gives the company clear differentiation, a strong clinical narrative, and a premium technology positioning. On the other hand, it exposes Sonendo to adoption risk, reimbursement and budget sensitivity at the dental-practice level, and the challenge of convincing practitioners to change established workflows. Competitive pressure comes from conventional endodontic tools and systems, alternative disinfection methods, and lower-cost treatment solutions. Sonendo therefore competes more on clinical differentiation and workflow value than on scale. Geographically, the company appears primarily centered on the U.S. market, with operations and corporate presence anchored in Southern California. Recent company communications indicate that management has been executing a strategic reset since early 2024, with priorities including revenue stabilization, gross margin improvement, lower operating expenses, and reduced cash burn. In 2025, Sonendo also completed a $5.0 million private placement and continued restructuring efforts, highlighting the company’s focus on liquidity and the path toward breakeven. For investors, Sonendo should be viewed as a niche dental-medtech small-cap with meaningful technology upside, but also elevated execution and financing risk. As a U.S. issuer tied to the healthcare sector, it remains a closely watched name for operational turnaround and insider-activity analysis.